Opus Genetics Key Fundamental And Technical Indicators

Stocks . USA . 
Stock . Opus Genetics
IRD Stock   5.12  0.13  2.61%   
Opus Genetics's key ratios are summarized here so margins, returns, and balance-sheet strength can be compared at a glance. Certain ratio combinations -- such as high leverage with low interest coverage -- are traditionally watched as stress markers. In Current reporting cycle, Opus Genetics posts the short-cycle RSI reading of 54, consistent with balanced price action. A reading near 50 often appears during transitional phases when a prior trend is consolidating before resuming or reversing.
Momentum
OversoldOverbought
54 · Neutral
As of the 12th of May 2026, Opus Genetics prints 5.12 per share on the tape. Available indicator data includes Semi Deviation of 3.45, risk adjusted performance of 0.2485, and Coefficient Of Variation of 396.31. Market dynamics are evaluated through structured indicator analysis. Indicator dispersion is evaluated across similar market participants.
Cycles Operators Shifting Impulse Patterns Depth Overlaps Statistics Volatility Volume
Financial statement analysis for Opus Genetics combines income trends, asset quality, and liquidity assessment. Key drivers essential for forming an accurate valuation are shown below: Opus Genetics' financial statements quantify how the business generates, deploys, and retains capital. Key drivers are highlighted below:
 Gross Profit
-16.62 million
 Market Capitalization
356.3 million
 Enterprise Value Revenue
22.05
 Revenue
14.2 million
 Earnings Share
-0.80
A total of one hundred twenty fundamental trend indicators are available for Opus Genetics, each providing a different lens on financial performance. Comparing Opus Genetics' current financial profile with its own history from 2010 to 2026 is essential for evaluating forward viability. As of December 31, 2025, Market Cap remains stable near $1.25 billion. Also, Enterprise Value remains stable near $1.21 billion. To filter equities by specific fundamental criteria, continue to Equity Screeners. Users can apply multiple criteria simultaneously for targeted results.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Profitability
Analysis
Details
Earnings
Projections
Details

Operating Margin TTM Peer Comparison

Stock peer comparison using Operating Margin TTM is a widely accepted framework for evaluating Opus Genetics within its group. Investors who find Opus Genetics' Operating Margin TTM more favorable than peers may view Opus Genetics as attractively valued. Peer dispersion in Operating Margin TTM across the group provides context for evaluating Opus Genetics' competitive positioning. This Operating Margin TTM peer data helps refine the view of Opus Genetics' relative attractiveness.
Opus Genetics is currently under evaluation for operating margin ttm relative to top peers.

Important Fundamentals

Return On Equity TTM-2.42
Return On Asset TTM-0.55
Operating Margin TTM-2.96
Current Valuation313.05 M
Shares Outstanding71.4 M
Shares Owned By Insiders15.22 %
Shares Owned By Institutions37.87 %
Number Of Shares Shorted1.81 M
Price To Book TTM23.26 X
Price To Sales TTM25.10 X
Revenue TTM14.2 M
Gross Profit TTM-16.62 M
EBITDA TTM-38.6 M
Net Income TTM-49.59 M
Total Debt TTM34.9 M
Book Value Per Share TTM0.22 X
Cash Flow From Operations TTM-35.25 M
Short Ratio TTM2.69 X
Earnings Per Share-0.80 X
Target Price10.2
Number Of Employees27
Trailing Beta0.63
Market Capitalization TTM356.3 M
Total Asset TTM50.24 M
Retained Earnings TTM-188.59 M
Working Capital TTM42.26 M
Net Asset50.24 M

Financial Metrics, Fundamentals & Methodology

Reviewing Opus Genetics means checking how consistently revenue is converted into earnings and cash flow. Operating leverage helps explain how sensitive earnings may be to slower demand or higher costs. Latest reported fundamentals for Opus Genetics include revenue of 14.2 million, EPS loss of 0.8, negative operating margin of 2.96% as of the latest reporting period.

Reported values for Opus Genetics are derived from periodic company reporting and market reference feeds and standardized for analysis. Sell-side coverage, where present, supplements the data shown. Accounting-line values follow GAAP or IFRS structures as published in issuer filings.

Editorial review and methodology oversight provided by: Michael Smolkin, Member of Macroaxis Board of Directors


 
Tools
Analysis
Directory
Company
2026 Macroaxis LLC Made with in San Francisco
Privacy Terms Widgets Feedback
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and conditions page.